Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 8 |
| List of Tables | 8 | 3 |
| List of Figures | 11 | 2 |
| Orphan Disease Therapeutics in Genetic Disorders to 2018 Introduction | 13 | 1 |
| Orphan Disease Therapeutics in Genetic Disorders to 2018 Market Overview | 14 | 12 |
| Introduction | 14 | 1 |
| Orphan Disease Regulation and Incentives | 14 | 2 |
| Revenue Forecasts for Orphan Disease Therapeutics in Genetic Disorders | 16 | 1 |
| Revenue | 16 | 1 |
| Revenue Share by Geography | 17 | 1 |
| Annual Cost of Treatment | 18 | 1 |
| Global Treatment Usage Patterns | 19 | 1 |
| Diseased Population | 19 | 1 |
| Treatment Seeking Population | 20 | 1 |
| Diagnosed Population | 21 | 1 |
| Prescription Population | 22 | 1 |
| Drivers and Restraints for Orphan Genetic Disease Therapeutics Market | 23 | 1 |
| Drivers for Orphan Genetic Disease Therapeutics Market | 23 | 1 |
| Smaller Companies Benefit from the Development of Niche Products | 23 | 1 |
| Low Competition Encourages Companies to Target Rare Diseases | 23 | 1 |
| Government Incentives Encourage Interest and Development | 24 | 1 |
| Larger Companies are Increasingly Entering into M&As and Forming Partnerships with Small Companies and Academia | 24 | 1 |
| Targeting Non-orphan Indications with Orphan Drugs Increases Market Potential for Orphan Drugs | 24 | 1 |
| Generic Drugs are Not a Threat to Disease-modifying Therapies | 24 | 1 |
| Restraints for Orphan Genetic Disease Therapeutics Market | 25 | 1 |
| Conducting Clinical Trials for Orphan Genetic Diseases is Difficult | 25 | 1 |
| Unmet Needs | 25 | 1 |
| Opportunities | 25 | 1 |
| Orphan Disease Therapeutics in Genetic Disorders to 2018 Geographical Landscape | 26 | 18 |
| The US | 26 | 1 |
| Revenue | 26 | 1 |
| Annual Cost of Treatment | 27 | 1 |
| Treatment Usage Patterns | 28 | 1 |
| Diseased Population | 28 | 1 |
| Treatment Seeking Population | 29 | 1 |
| Diagnosed Population | 30 | 1 |
| Prescription Population | 31 | 1 |
| Top Five Countries of Europe | 32 | 1 |
| Revenue | 32 | 1 |
| Annual Cost of Treatment | 33 | 1 |
| Treatment Usage Patterns | 34 | 1 |
| Diseased Population | 34 | 1 |
| Treatment Seeking Population | 35 | 1 |
| Diagnosed Population | 36 | 1 |
| Prescription Population | 37 | 1 |
| Japan | 38 | 1 |
| Revenue | 38 | 1 |
| Annual Cost of Treatment | 39 | 1 |
| Treatment Usage Patterns | 40 | 1 |
| Diseased Population | 40 | 1 |
| Treatment Seeking Population | 41 | 1 |
| Diagnosed Population | 42 | 1 |
| Prescription Population | 43 | 1 |
| Orphan Disease Therapeutics in Genetic Disorders to 2018 Therapeutic Landscape | 44 | 52 |
| Cystic Fibrosis | 44 | 1 |
| Introduction | 44 | 1 |
| Symptoms | 45 | 1 |
| Diagnosis | 45 | 1 |
| Treatment Flow | 46 | 1 |
| Revenue | 47 | 1 |
| Branded and Generic Market Share | 48 | 1 |
| Annual Cost of Treatment | 49 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Diseased Population | 50 | 1 |
| Treatment Seeking Population | 51 | 1 |
| Diagnosed Population | 52 | 1 |
| Prescription Population | 53 | 1 |
| Marketed Products | 54 | 1 |
| KALYDECO (Ivacaftor, VX-770) | 54 | 1 |
| TOBI | 54 | 1 |
| Pulmozyme (dornase alfa) | 55 | 1 |
| Creon (pancrelipase capsules) | 56 | 1 |
| Cayston (aztreonam for inhalation solution) | 56 | 1 |
| Colistimethate sodium (Colistin, Colomycin Injection, Promixin, Coly-Mycin M) | 57 | 1 |
| Drivers and Restraints for the Cystic Fibrosis Therapeutics Market | 58 | 1 |
| Drivers for the Cystic Fibrosis Therapeutics Market | 59 | 1 |
| Barriers for the Cystic Fibrosis Therapeutics Market | 60 | 1 |
| Duchenne Muscular Dystrophy | 61 | 1 |
| Introduction | 61 | 1 |
| Symptoms | 61 | 1 |
| Treatment Algorithm | 62 | 1 |
| Revenue | 63 | 1 |
| Branded and Generic Market Share | 64 | 2 |
| Annual Cost of Treatment | 66 | 1 |
| Treatment Usage Patterns | 67 | 1 |
| Diseased Population | 67 | 1 |
| Treatment Seeking Population | 68 | 1 |
| Diagnosed Population | 69 | 1 |
| Prescription Population | 70 | 1 |
| Marketed Therapies | 71 | 1 |
| Drivers and Restraints for Duchenne Muscular Dystrophy Therapeutics Market | 71 | 1 |
| Drivers for Duchenne Muscular Dystrophy Therapeutics Market | 71 | 1 |
| Restraints for Duchenne Muscular Dystrophy Therapeutics Market | 72 | 1 |
| Fabry Disease | 73 | 1 |
| Introduction | 73 | 1 |
| Symptoms | 73 | 1 |
| Treatment Flow | 74 | 1 |
| Revenue | 74 | 1 |
| Branded and Generic Market Share | 75 | 1 |
| Annual Cost of Treatment | 76 | 2 |
| Treatment Usage Patterns | 78 | 1 |
| Diseased Population | 78 | 1 |
| Treatment Seeking Population | 79 | 1 |
| Diagnosed population | 80 | 1 |
| Prescription Population | 81 | 1 |
| Drivers and Restarints for Fabry Disease Therapeutics Market | 82 | 1 |
| Drivers and Restarints for Fabry Disease Therapeutics Market | 82 | 1 |
| Restraints for Fabry Disease Therapeutics Market | 83 | 1 |
| Marketed Products | 83 | 1 |
| Fabrazyme | 83 | 1 |
| Replagal | 84 | 1 |
| Pompe Disease | 85 | 1 |
| Introduction | 85 | 1 |
| Symptoms | 86 | 1 |
| Treatment Flow Algorithm | 86 | 1 |
| Revenue | 87 | 1 |
| Generic Share | 88 | 1 |
| Annual Cost of Treatment | 88 | 1 |
| Treatment Usage Patterns | 89 | 4 |
| Drivers for Pompe Disease Therapeutics Market | 93 | 1 |
| Restraints for the Pompe Disease Therapeutics Market | 94 | 1 |
| Marketed Products | 94 | 1 |
| Myozyme/Lumizyme | 94 | 1 |
| Efficacy | 94 | 2 |
| Orphan Disease Therapeutics in Genetic Disorders to 2018 Pipeline Analysis | 96 | 15 |
| Introduction | 96 | 1 |
| R&D Pipeline Cystic Fibrosis | 97 | 1 |
| Pre-Clinical Stage | 97 | 1 |
| Phase I | 98 | 1 |
| Phase II | 99 | 3 |
| Phase III | 102 | 1 |
| Promising Drugs in the Pipeline | 102 | 1 |
| Bramitob (NDA Filed) | 102 | 1 |
| Bronchitol (NDA Filed) | 103 | 1 |
| Colobreathe | 103 | 1 |
| Aeroquin | 103 | 1 |
| Ataluren | 103 | 1 |
| Pari Tobramycin 100 | 103 | 1 |
| Spiriva | 104 | 1 |
| R&D Pipeline Duchenne Muscular Dystrophy | 104 | 1 |
| Pre-Clinical | 104 | 1 |
| Phase I | 105 | 1 |
| Phase II | 106 | 1 |
| Phase III | 106 | 1 |
| Promising Molecules in the Pipeline | 107 | 1 |
| PRO051 | 107 | 1 |
| Catena (Idebenone) | 107 | 1 |
| Atularen | 107 | 1 |
| AVI-4658 (Eteplirsen) | 107 | 1 |
| SMT C1100 | 107 | 1 |
| ACE-031 | 107 | 1 |
| R&D Pipeline Fabry Disease | 108 | 1 |
| Pre-Clinical | 108 | 1 |
| Phase II | 109 | 1 |
| Phase III | 109 | 1 |
| Amigal | 109 | 1 |
| R&D Pipeline Pompe Disease | 110 | 1 |
| Pre-Clinical | 110 | 1 |
| Phase II | 110 | 1 |
| BMN-701 | 110 | 1 |
| Orphan Disease Therapeutics in Genetic Disorders to 2018 Competitive Landscape | 111 | 8 |
| Competitive Profiling | 111 | 1 |
| GlaxoSmithKline | 111 | 1 |
| Overview | 111 | 1 |
| SWOT | 111 | 1 |
| Prosensa | 112 | 1 |
| Overview | 112 | 1 |
| SWOT | 112 | 1 |
| Santhera | 112 | 1 |
| Overview | 112 | 1 |
| SWOT | 113 | 1 |
| AVI BioPharma | 113 | 1 |
| Overview | 113 | 1 |
| SWOT | 113 | 1 |
| Genzyme (Sanofi Subsidiary) | 114 | 1 |
| Overview | 114 | 1 |
| SWOT | 114 | 1 |
| Shire | 114 | 1 |
| Overview | 114 | 1 |
| SWOT | 115 | 1 |
| PTC Therapeutics | 115 | 1 |
| Overview | 115 | 1 |
| SWOT | 115 | 1 |
| Novartis | 116 | 1 |
| Overview | 116 | 1 |
| SWOT | 116 | 1 |
| Genentech (Roche) | 117 | 1 |
| Overview | 117 | 1 |
| SWOT | 117 | 1 |
| Gilead | 117 | 1 |
| Overview | 117 | 1 |
| SWOT | 118 | 1 |
| Orphan Disease Therapeutics in Genetic Disorders to 2018 Strategic Consolidations | 119 | 14 |
| M&A Landscape | 119 | 1 |
| Key Deals | 119 | 1 |
| Axcan Pharma Acquires Mpex Pharmaceuticals for $223.6m (August 31, 2011) | 119 | 1 |
| Axcan Pharma Acquires Eurand (February 11, 2011) | 119 | 1 |
| Gilead Sciences Acquires Corus Pharma (August 11, 2006) | 120 | 1 |
| Sanofi Completes Acquisition of Genzyme (April 8, 2011) | 120 | 1 |
| M&A Deals by Year | 121 | 1 |
| M&A Deals by Geography | 121 | 1 |
| M&A Deals by Value | 122 | 1 |
| R&D Licensing Agreements | 122 | 1 |
| Key Deals | 122 | 1 |
| Proteostasis Therapeutics Enters into Licensing Agreement with Harvard University (April 26, 2011) | 122 | 1 |
| Forest Laboratories Terminates its Licensing Agreement with Gruenenthal (December 20, 2010) | 123 | 1 |
| Kamada Expands Licensing Agreement with Pari (February 25, 2008) | 123 | 1 |
| Aridis Pharmaceuticals Enters into Licensing Agreement with University of Iowa Research | 123 | 1 |
| BioMarin Enters into Licensing Agreement with University of California | 123 | 1 |
| Gilead Sciences Enters into Licensing Agreement with Parion Sciences | 123 | 1 |
| Brown University Enters into Licensing Agreement with Tivorsan (September 21, 2010) | 124 | 1 |
| Shire Enters into Licensing Agreement with Acceleron Pharma for ACE-031 (September 9, 2010) | 124 | 1 |
| GlaxoSmithKline Expands Licensing Agreement with Prosensa (June 23, 2010) | 124 | 1 |
| BioMarin Pharmaceutical Terminates its Licensing Agreement with Summit Corporation | 125 | 1 |
| Amsterdam Molecular Therapeutics Enters into Licensing Agreement with La Sapienza University of Rome (May 22, 2008) | 125 | 1 |
| AVI BioPharma Enters into Agreement with Ercole Biotech | 125 | 1 |
| Santhera Pharmaceuticals Enters into Option and Licensing Agreement with Genzyme | 126 | 1 |
| Amicus Therapeutics Terminates Licensing Agreement with Shire (October 29, 2009) | 126 | 1 |
| Deals by Year | 126 | 1 |
| Deals by Geography | 127 | 1 |
| Co-Development Agreements | 127 | 1 |
| Genzyme Enters into Research Agreement with Cystic Fibrosis Foundation Therapeutics | 127 | 1 |
| Vertex Pharmaceuticals Extends Co-Development Agreement with Cystic Fibrosis Foundation | 127 | 1 |
| GlaxoSmithKline Enters into Co-Development Agreement with McGill University | 128 | 1 |
| Sanofi Enters into Strategic Alliance with Regulus Therapeutics | 128 | 1 |
| FoldRx Enters into Co-Development Agreement with Cystic Fibrosis Foundation | 128 | 1 |
| Predix Pharmaceuticals Expands Co-Development Agreement with Cystic Fibrosis Foundation | 129 | 1 |
| Nektar Therapeutics Signs Co-Development Agreement with Bayer HealthCare | 129 | 1 |
| PTC Therapeutics Expands its Collaboration with Parent Project Muscular Dystrophy | 130 | 1 |
| Galapagos Enters into Agreement with Charley s Fund and the Nash Avery Foundation | 130 | 1 |
| AVI BioPharma Enters into Agreement with Action Duchenne | 130 | 1 |
| Amsterdam Molecular Therapeutics Enters into Co-Development Agreement with National Institutes of Health | 130 | 1 |
| PTC Therapeutics Terminates Co-Development Agreement with Genzyme | 131 | 1 |
| Deals by Year | 132 | 1 |
| Deals by Geography | 132 | 1 |
| Appendix | 133 | 6 |
| Market Definitions | 133 | 1 |
| Abbreviations | 133 | 1 |
| Sources | 134 | 1 |
| Research Methodology | 135 | 4 |
| Coverage | 135 | 1 |
| Secondary Research | 135 | 1 |
| Primary Research | 136 | 1 |
| Forecasting | 136 | 1 |
| Geographical Landscape | 137 | 1 |
| Pipeline Analysis | 137 | 1 |
| Competitive Landscape | 137 | 1 |
| Expert Panel Validation | 138 | 1 |
| Contact Us | 138 | 1 |
| Disclaimer | 138 | 1 |